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1 Purpose 
To describe the procedures related to the completion of case report forms, source documents, 
record keeping and archiving. 
2 Responsibility  /  Scope 
This standard applies to all Queensland Health employees (including visiting medical officers, 
visiting health professionals, contractors, consultants and volunteers) who propose to 
undertake, administrate, review and/or govern human research involving Queensland Health 
patients and staff.  
3 Applicability 
Principal Investigator, Associate/Sub-Investigator(s), Research Coordinators and other staff 
delegated project-related activities by the Principal Investigator. 
4 Procedure 
4.1.  Completion of case report forms (CRFs and e-CRFs) 
The investigator(s)/ institution should: 
  Ensure the accuracy, completeness, legibility, and timeliness of data collection is 
adhered to according to the protocol. ICH GCP 4.9.1 
  Ensure the accuracy, completeness, legibility, and timeliness of data collected in the 
CRFs or e-CRFs and other required documents submitted to the sponsor or 
Coordinating Investigator is adhered to according to the protocol. 
  Ensure that data reported on the CRF or e-CRFs, which is derived from source 
documents, is consistent with the source documents. Any discrepancies should be 
explained. ICH GCP 4.9.2 
  Ensure that any change or correction to a paper CRF is made with a single stroke 
through the incorrect information, dated, initialled, and explained (if necessary). The 
original entry should not be obscured (i.e. an audit trail should be maintained). 
eCRF’s are required to have an inbuilt correction and audit process. However, if 
there is no inbuilt audit trail, see below. ICH GCP 4.9.3 
  Retain records of the changes and corrections (eg data queries) to demonstrate an 
audit trail. 
 
4.2.  Source documents, record keeping and archiving 
The investigator(s) should: 
  Keep original source documents (where the data was first recorded) and take 
measures to prevent accidental or premature destruction of these documents. ICH 
GCP 4.9.7 
  Ensure that any change or correction to any source data is made with a single stroke 
through the incorrect information, dated, initialled, and explained (if necessary). The 
original entry should be not obscured (i.e. an audit trail should be maintained). This 
applies to written changes or corrections. ICH GCP 4.9.3 
  Where an investigator is using their own electronic CRF documents, changes and 
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degree of change) should be altered to reflect the changed data. An explanation of 
the changes should be added in the footer, or noted in a record of changes. ICH 
GCP 5.5.3 
  Ensure that a copy of the signed and completed Participant Information Sheet and 
Consent form has been filed in the appropriate place in the hospital chart (follow local 
Medical Records guidelines). (Institutional guidelines) 
  Maintain the trial documents as specified in QH SOP 2 appendix 2 - The Study Site 
Master File and Essential Documents and as required by the applicable regulatory 
requirement(s) and take measures to prevent accidental or premature destruction of 
these documents. ICH GCP 4.9.4 
  Ensure that upon request of the monitor, auditor, HREC, Governance Officer or 
regulatory authority, make available for direct access, all requested project related 
records as outlined in the Clinical Trial Agreement and Patient Information Sheet and 
Informed Consent Form. ICH GCP 4.9.7 
  Ensure that in those instances where a study participant does not have a medical 
record for that institution, that a medical record is created in accordance with local 
hospital requirements. (Institutional guidelines) 
 
4.3. Archiving 
  Study documentation should be maintained as specified in the Australian Code for 
the Responsible Conduct of Research (Part A, Section 2.1) 
(http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/r39.pdf) as 
indicated below: 
  For short term research projects, that are for assessment purposes only (eg 
research projects completed by students), retention of research data for 12 
months after completion of the project may be sufficient. 
  For clinical trials, data should be retained for a minimum of 15 years for adult 
studies or 25 years for paediatric studies after formal notification is received 
that all study procedures are completed and the study is closed. 
  For areas such as gene therapy, research data must be retained permanently 
(eg patient records). 
  If the work has community or heritage value, research data should be kept 
permanently, preferably within a national collection. 
  For legal reasons, sites may consider indefinite archiving periods. 
  The TGA position on document retention states: 
“The TGA requires records to be retained by the sponsor for 15 years following the 
completion of a clinical trial. However, in Australia the overriding consideration for 
sponsors with respect to record retention is the issue of product liability and the 
potential need for sponsors of products to produce records at any time during, and 
possibly beyond, the life of a product in the event of a claim against the sponsor as a 
result of an adverse outcome associated with the use of the product”. 
  ICH-GCP requirements for record retention state: 
“Ensure that essential documents are retained until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region or at least 2 years have 
elapsed since the formal discontinuation of clinical development of the investigational 
product. These documents should be retained for a longer period however if required 
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  Original documents should be retained. Scanned copies are acceptable if certified as 
true and correct. ICH GCP 1.51 and 1.52 
  A Document Retention Sticker must be placed on all volumes of the Participant’s 
medical record in an appropriate position as guided by local Medical Records 
practice. (Institutional guidelines) 
  Queensland Government has a “Standing Offer” arrangement for the provision of 
records storage, retrieval and destruction services (off-site) for non-commercially 
sponsored research. For details, refer to the following weblink: 
http://qcd.govnet.qld.gov.au/Pages/Details.aspx?SOANumber=QGCPO747-08. This 
service is NOT available for commercially sponsored research. 
  For commercially sponsored research, private archiving arrangements should be 
negotiated with the study sponsor (and the site Medical Records Department, if 
applicable at that site) prior to commencement of the study. These details should be 
noted in the study contract. 
  Identifiable information that is part of a commercially sponsored clinical trial (eg 
Participant Identification Log and Participant Information Sheet and Consent Forms) 
should be separated from the main study documents, and archived with the Principal 
Investigator – in case identification of participants is required at a later time. A 
reference to the type and location of these documents should be filed with the 
archived study documents. ICH GCP 8.3.21 
  A copy of the Subject Identification Log listing all contact details plus hospital specific 
medical record number to be used for future reference should be kept in a file with 
the Principal Investigator to be used for future reference. 
5 Glossary 
Case Report Form (CRF and e-CRF) 
A printed, optical, or electronic document designed to record all of the protocol required 
information to be reported to the sponsor on each trial subject. 
 
Good Clinical Practice (GCP) 
A standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and 
reporting of clinical trials that provides assurance that the data and reported results are credible 
and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected. 
 
Human Research Ethics Committee (HREC) 
A body which reviews research proposals involving human participants to ensure that they are 
ethically acceptable and in accordance with relevant standards and guidelines. 
The National Statement requires that all research proposals involving human participants be 
reviewed and approved by an HREC and sets out the requirements for the composition of an 
HREC. 
 
International Conference on Harmonisation (ICH) 
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use is a joint initiative involving both regulators and research-based 
industry focusing on the technical requirements for medicinal products containing new drugs. 
 
 QH GCP SOP 7:  Case Report Forms, Source Documents, Record Keeping and Archiving 
Prepared by the Research Ethics and Governance Unit| May 2010                                                          5 of 5 
http://www.health.qld.gov.au/ohmr | ohmr@health.qld.gov.au | 3405 6121 
Based on, and with permission of the Victorian Managed Insurance Authority – VMIA GCP SOPS 
Reviewed by the QH Clinical Research Coordinators Network May 2010 
Investigator 
An individual responsible for the conduct of a clinical trial at a trial site and ensures that it 
complies with GCP guidelines. If a trial is conducted by a team of individuals at a trial site, one 
investigator should be designated as the responsible leader of the team and should be called the 
site Principal Investigator. In this instance they may delegate tasks to other team members. 
 
Source Documents 
Original documents (where the data was first recorded), data, and records (e.g. medical/hospital 
records, clinical and office charts, laboratory notes, memoranda, subjects' diaries or evaluation 
checklists, pharmacy dispensing records, recorded data from automated instruments, copies or 
transcriptions certified after verification as being accurate copies, microfiches, photographic 
negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, 
at the laboratories and at medico-technical departments involved in the clinical trial). 
 
Sub / Associate Investigator 
Any individual member of the clinical trial team designated and supervised by the investigator at a 
trial site to perform trial-related procedures and/or to make important trial-related decisions (e.g., 
associates, residents, research fellows, clinical research coordinators. The P.I. will designate who 
will be nominated as Associate Investigators for that site. 
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